---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-002"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-002. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 30 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence/op-1250-002"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-002

<a id="heading-3.1.4"></a>

## 3.1.4 OP-1250-002

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Study purpose

> “Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).”

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.1-2"></a>

#### Primary objectives by study part

> “Primary objectives: Determine MTD and/or RP2D, safety and tolerability, and PK of palazestrant in combination with palbociclib”
> “Primary objectives: Safety and tolerability and PK of palazestrant at RP2D in combination with palbociclib”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Registry dates and enrollment

| Item | Value |
| --- | --- |
| Study start (actual) | “2021-12-10” |
| Primary completion (estimated) | “2026-03” |
| Enrollment (actual) | “60” |

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.2-2"></a>

#### Enrollment period, sites, and data cutoff

> “46 patients were enrolled at 8 sites between January 2022 and August 2023. Data cutoff date for this analysis was September 15, 2023.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.2-3"></a>

#### Palbociclib supply agreement

> “The companies’ previous agreement was established in November 2020 to evaluate palazestrant in combination with palbociclib (IBRANCE®) in patients with recurrent, locally advanced or metastatic ER+/HER2- breast cancer.”

Source: [Olema Oncology Pfizer atirmociclib agreement announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-agreement-pfizer)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Open-label dose escalation and expansion

> “This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib”

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.3-2"></a>

#### Two-part structure

> “The OP-1250-002 study comprises two parts: a dose-escalation phase followed by a dose-expansion phase.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Key eligibility criteria

> “Women (regardless of menopausal status) or men with HR+/HER2– advanced or metastatic breast cancer”
> “Zero or one prior endocrine therapy ± a CDK4/6 inhibitor for locally advanced or metastatic disease”
> “one prior line of chemotherapy for advanced or metastatic breast cancer was allowed”
> “Evaluable disease (measurable or non-measurable by RECIST 1.1)”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.4-2"></a>

#### Registry exclusion criteria

> “Significant cardiovascular disease”
> “Significant ECG abnormalities”
> “History of pulmonary embolism or high risk of thrombosis”

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Dose escalation and dose expansion regimens

> “Patients received 30, 60, 90, or 120 mg palazestrant QD plus 125 mg palbociclib PO QD on days 1–21 of each 28-day treatment cycle.”
> “Dose-expansion (ongoing) patients receive 120 mg palazestrant plus 125 mg palbociclib QD.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Dose-limiting Toxicities as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Registry primary outcomes

| Primary outcome | Time frame |
| --- | --- |
| “Incidence of Dose Limiting Toxicities” | “From Cycle 1 Day 1 through C1 Day 28” |
| “Characterization and Incidence in Adverse Events and Serious Adverse Events” | “From initial inform consent date through 30 days post last dose” |
| “Plasma levels of OP-1250 and Palbociclib” | “Up to 9 months” |

Source: [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.6.1-2"></a>

##### Secondary objectives

> “Secondary objectives: ORR (CR + PR), CBR (CR + PR + SD ≥24 weeks)”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Enrolled and planned participants, September 2023 data cutoff

> “Thirty-four patients were enrolled in this part; approximately 45 patients are planned for enrollment in the dose-expansion phase.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.7.1-2"></a>

##### Participants by palazestrant dose, September 2023 data cutoff

| Palazestrant dose | Participants |
| --- | --- |
| 30 mg | “30 mg (n=3)” |
| 60 mg | “60 mg (n=3)” |
| 90 mg | “90 mg (n=3)” |
| 120 mg | “120 mg (n=37)” |
| Total | “Total (N=46)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.7.1-3"></a>

##### Earlier interim analysis population

> “29 patients were enrolled as of March 8, 2023”

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Clinical benefit rate and ESR1 analysis populations

> “Clinical benefit rate was 46% (12/26 patients) in all patients and 60% (6/10) in patients with ESR1 mutation in ctDNA at baseline.”
> “ctDNA from 37 patients was available at the time of data cutoff for ESR1 mutation evaluation.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.7.2-2"></a>

##### Pharmacokinetic sampling schedule

> “Plasma samples for OP-1250 assessment were collected on C1 day (D) 1 (C1D1), C1D2/D8/D15, C2D15/D16, C3D1/D15, C5D1, C7D1, and C9D1. For palbociclib, they were collected on C1D15, C2D15, and C3D15.”

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Treatment status and reasons for discontinuation, September 2023 data cutoff

| Status | Total (N=46), n (%) |
| --- | --- |
| Treatment ongoing | “22 (48)” |
| Treatment discontinued | “24 (52)” |
| Discontinued for disease progression | “18 (39)” |
| Discontinued for physician decision | “3 (7)” |
| Discontinued for patient decision | “2 (4)” |
| Discontinued for adverse event | “1 (2)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Baseline demographics and disease characteristics, September 2023 data cutoff

| Characteristic | Total (N=46), n (%) |
| --- | --- |
| Median age, years (range) | “63.5 (30–77)” |
| Female sex | “45 (98)” |
| Premenopausal | “4 (9)” |
| ECOG performance status 0 | “31 (67)” |
| ECOG performance status 1 | “15 (33)” |
| Measurable disease | “36 (78)” |
| Visceral disease | “20 (44)” |
| One prior line of therapy for advanced disease | “34 (74)” |
| One prior line of endocrine therapy for advanced disease | “40 (87)” |
| Prior CDK4/6 inhibitor for advanced disease | “33 (72)” |
| Prior aromatase inhibitor for advanced disease | “35 (76)” |
| Prior fulvestrant for advanced disease | “5 (11)” |
| Prior chemotherapy for advanced disease | “10 (22)” |
| ESR1 mutation at baseline (ctDNA) | “16/37 (43)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.2-2"></a>

##### Prior CDK4/6 inhibitor exposure

> “33 (72%) patients received prior treatment with CDK4/6 inhibitors for advanced disease (palbociclib, n=22; ribociclib, n=10; both palbociclib and ribociclib, n=1).”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Responses, clinical benefit, and treatment duration, September 2023 data cutoff

> “Partial responses were observed in seven patients. (2 cPR; 5uPR)”
> “Clinical benefit rate was 46% (12/26 patients) in all patients and 60% (6/10) in patients with ESR1 mutation in ctDNA at baseline.”
> “53% of patients had any reduction in target lesion size.”
> “Longest duration of treatment is 76 weeks and ongoing.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.3-2"></a>

##### Clinical benefit rate without prior CDK4/6 inhibitor treatment

> “In patients naïve to prior CDK4/6 inhibitor treatment, the CBR was 71%.”

Source: [Olema Oncology SABCS 2023 combination results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-demonstrates-attractive)

<a id="topic-3.1.4.8.3-3"></a>

##### Pharmacokinetic interaction results

> “There was no effect of palazestrant (30-120 mg) on palbociclib 125 mg exposure parameters.”
> “Cmax ratios of combination therapy to monotherapy ranged from 96% to 107%.”
> “Palbociclib 125 mg did not affect palazestrant (30-120 mg) exposure parameters.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.3-4"></a>

##### Palazestrant steady-state pharmacokinetics with palbociclib 125 mg, March 2023 data cutoff

| Palazestrant dose | Cmin (ng/mL) | Cmax (ng/mL) | Cavg (ng/mL) | Tmax (h) | AUC0–24 (ng*h/mL) |
| --- | --- | --- | --- | --- | --- |
| “30 mg (n=2)” | “61.2 (38%)” | “136 (49%)” | “94.7 (13%)” | “2.0 (2.0–2.0)” | “2270 (13%)” |
| “60 mg (n=3)” | “186 (52%)” | “337 (24%)” | “253 (43%)” | “2.0 (2.0–2.0)” | “6070 (43%)” |
| “90 mg (n=3)” | “199 (55%)” | “549 (63%)” | “341 (49%)” | “2.0 (2.0–4.0)” | “8180 (49%)” |
| “120 mg (n=12)” | “313 (43%)” | “573 (43%)” | “429 (39%)” | “4.0 (2.0–6.0)” | “10300 (39%)” |

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

Additional sources: [Chan et al. (2024)](https://aacrjournals.org/cancerres/article/84/9_Supplement/PS15-04/744001/Abstract-PS15-04-A-Phase-1b-2-study-of)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Dose-limiting toxicities and overall severity

> “No DLTs were observed during the dose-escalation part of the study.”
> “Most treatment-emergent adverse events (TEAEs) were grade 1 or 2.”
> “There were no dose-related increases in incidence or severity of TEAEs.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.5-2"></a>

##### Treatment-emergent adverse events in at least 20% of participants, total population (N=46), n (%)

| Event | All grades | Grade 3 | Grade 4 |
| --- | --- | --- | --- |
| Neutropenia (combined term) | “40 (87)” | “28 (61)” | “5 (11)” |
| Nausea | “26 (57)” | “0” | “0” |
| Vomiting | “17 (37)” | “0” | “0” |
| Anemia | “12 (26)” | “1 (2)” | “0” |
| Diarrhea | “11 (24)” | “0” | “0” |
| Constipation | “10 (22)” | “1 (2)” | “0” |
| Fatigue | “10 (22)” | “1 (2)” | “0” |
| Thrombocytopenia | “10 (22)” | “0” | “0” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.5-3"></a>

##### Dose reductions and discontinuations

> “One patient discontinued both drugs due to an AE of nausea concurrent with documented disease progression.”
> “No patients had dose reduction of palazestrant for neutropenia. Eleven patients had dose reduction of palbociclib for neutropenia.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-3.1.4.8.5-4"></a>

##### Fatal events in the earlier interim analysis

> “There were no treatment-related fatal events”

Source: [Chan et al. (2023a)](https://olema.com/wp-content/uploads/2023/05/Olema_ESMO-BC_OP1250-Poster_FINAL_5-11-23.pdf)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

OP-1250-002 is an open-label phase 1b dose-escalation and dose-expansion study. Eligibility allowed zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease, which admits participants outside previously treated disease; 33 of 46 participants (72%) had received a prior CDK4/6 inhibitor. The CBR is based on 26 evaluable participants overall and 10 with ESR1 mutations, and circulating tumor DNA for ESR1 testing was available for 37 participants. The reported results have a data cutoff of September 15, 2023, at which 22 participants (48%) remained on treatment and the data were described as maturing. The registry lists an actual enrollment of 60 participants, whereas the reported analysis includes 46.

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf); [ClinicalTrials.gov NCT05266105](https://clinicaltrials.gov/study/NCT05266105)

<a id="topic-3.1.4.9-2"></a>

#### Immature efficacy data and incomplete ESR1 testing

> “Data are maturing; 22 patients (48%) remain on treatment.”
> “ctDNA from 37 patients was available at the time of data cutoff for ESR1 mutation evaluation.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
